JPRN-UMIN000020329招募中未知
Remission induction with rituximab in Japanese patients with ANCA-associated vascutlitis - RemIRIT
The strategic study group to establish evidences for the treatment guidelines of intractable vasculitis0 个研究点目标入组 50 人开始时间: 2016年1月25日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patient lower than 20 years-old
研究者
相似试验
未知
2 期
Japanese Phase II Study of Rituximab in combination with FC-chemotherapy in patients with previously untreated Chronic Lymphocytic LeukemiaJPRN-jRCT2080222236ZENYAKU KOGYO CO., LTD.6
已完成
3 期
R-ITP: Clinical Evaluation of Rituximab in Primary Immune ThrombocytopeniaIdiopathic Thrombocytopenic PurpuraJPRN-jRCT1091220070Keio University School of Medicine , Yoshitaka miyakawa24
已完成
不适用
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20Multiple myeloma expressing CD20JPRN-UMIN000000531Zenyaku Kogyo Co., Ltd.39
招募中
不适用
A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly HLA-sensitized Transplant Patients.JPRN-UMIN000011914Transplantation Surgery, Hiroshima University Hospital30
尚未招募
不适用
Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphomaKCT0008105Chonnam National University Hospital Hwasun Hospital29